Von dem Buch From Clones to Claims haben wir 3 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Hans R. Jaenichen; Jürgen Maier; Leslie A. McDonell; James F. Haley; Yoshinori Hosoda: From Clones to Claims (ISBN: 9783452279996) in Englisch, Broschiert.Nur diese Ausgabe anzeigen…
67%: Haley, James F.;Jaenichen, Hans-Rainer;McDonell, Leslie;Hosoda, Yoshinori: From Clones to Claims: The European Patent Office's Case Law on the Patentability of Biotechnology. Inventions in Comparison to the United States and Japanese Proctice (ISBN: 9783452247384) 2006, Heymann, Köln [u.a.], 4. Ausgabe, in Englisch, Broschiert.Nur diese Ausgabe anzeigen…
51%: Jaenichen, Hans-Rainer;Meier, Jürgen;McDonell, Leslie A.;Haley, James F.;Hosoda, Yoshinori: From Clones to Claims: The European Patent Offices s Case Law on the Patentability of Biotechnology Inventions in Comparison to the United States and Japanese Practice (Hardback) (ISBN: 9783452274328) 2012, in Deutsch.Nur diese Ausgabe anzeigen…
From Clones to Claims - 16 Angebote vergleichen
| Preise | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Schnitt | € 268,00 | € 271,88 | € 268,00 | € 268,00 |
| Nachfrage |
1
From Clones to Claims - An Encyclopedia of the European Patent Office's Case Law on the Patentability of Biotechnology Inventions with a Comparison to the United States and Japanese Practice
~EN HC NWISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Heymanns, gebundenes Buch, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
From Clones to Claims: The Documentation for Biotechnology The classic `From Clones to Claims` provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO). Given the book`s comments and structure, the EPO`s jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO`s opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. Englisch, Buch.
From Clones to Claims: The Documentation for Biotechnology The classic `From Clones to Claims` provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO). Given the book`s comments and structure, the EPO`s jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO`s opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. Englisch, Buch.
2
From Clones to Claims (2015)
~EN NWISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Heymanns, Carl, neu.
Lieferung aus: Deutschland, Sofort lieferbar.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 01.12.2015.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 01.12.2015.
3
From Clones to Claims (2015)
~EN NWISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Heymanns, Carl, neu.
Lieferung aus: Deutschland, Sofort lieferbar.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 01.12.2015.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 01.12.2015.
4
Haley, J: From Clones to Claims (2015)
~EN NWISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Heymanns, neu.
Lieferung aus: Österreich, Versandfertig in 1 - 2 Wochen.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 11.2015.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 11.2015.
5
From Clones to Claims (2015)
~EN NWISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Heymanns, Carl, neu.
Lieferung aus: Deutschland, Lieferbar in 1 - 2 Wochen.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 11.2015.
The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: •which inventions are patentable •disclosure requirements for Claims •clarity of Claims •enabling disclosure •deposit of biological material •priority •novelty •inventive step •essentials of Supplementary Protection Certificates (SPCs) and •procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen; Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München; Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA; James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA; Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan, gebundene Ausgabe, 11.2015.
6
From Clones to Claims
~EN NW ABISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Heymann, Köln, Deutschland, neu, Hörbuch.
Lieferung aus: Deutschland, zwischen 5 - 7 Werktagen.
The Documentation for Biotechnology The classic "From Clones to Claims" provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: which inventions are patentable disclosure requirements for Claims clarity of Claims enabling disclosure deposit of biological material priority novelty inventive step essentials of Supplementary Protection Certificates (SPCs) and procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen, Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München, Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA, James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA, Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan.
The Documentation for Biotechnology The classic "From Clones to Claims" provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: which inventions are patentable disclosure requirements for Claims clarity of Claims enabling disclosure deposit of biological material priority novelty inventive step essentials of Supplementary Protection Certificates (SPCs) and procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context. The Authors: Dipl.-Biol. Dr. Hans-Rainer Jaenichen, Dipl.-Biol. Dr. Jürgen Meier, Patentanwälte, European Patent Attorneys/European Trademark & Design Attorneys, Vossius & Partner, München, Leslie A. McDonell, J.D., Attorney at Law, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. and Cambrindge, MA USA, James F. Haley, Jr., J.D., Ph.D., Attoney at Law, Fish & Neave Intellectual Property Group, Ropes & Gray LLP, New York, New York USA, Yoshinori Hosoda, Japanese Patent Attorney, Hosoda International Patent Office, Osaka, Japan.
7
/ Meier / McDonell / Haley jr / Hosoda | From Clones to Claims | Carl Heymanns | 6. Auflage | 2016 | Fachbuch
~EN NWISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Carl Heymanns, neu.
Konkurrenzlose Dokumentation der vollständigen Entwicklung der biotechnologischen Entscheidungen des EPA. Schneller Zugriff auf die Entscheidungspraxis zu den spezifischen Sach- und Verfahrensfragen durch die systematische Darstellung. The Documentation for Biotechnology The classic 'From Clones to Claims' provides a comparative analysis of European, US and Japanese patent practice in the biotechnology and pharmaceutical area. It systematically organizes the jurisprudence of the Boards of Appeal of the European Patent Office (EPO) according to the topics: which inventions are patentable disclosure requirements for Claims clarity of Claims enabling disclosure deposit of biological material priority novelty inventive step essentials of Supplementary Protection Certificates (SPCs) and procedural issues for examination and opposition proceedings Given the book's comments and structure, the EPO's jurisprudence is immediately accessible for specific areas of daily practice. For instance, if the question arises to what extent antibodies can be claimed and how enablement, novelty and inventive step of such claims are routinely assessed by the EPO, separate specialized chapters of the book can be consulted. In its analysis of the jurisprudence, the new edition comprises a presentation of the changes and developments relevant to inventions in the area of stem cells, plants, diagnostic assays and surgical methods. The specific changes in the options for filing divisional applications and the recent procedural restrictions concerning the filing of claim requests, documents and experimental evidence are also addressed. Based on the comparative evaluation with US and Japanese law and practice, the book can be used as a guide for preparing European patent applications that can be sustained in these other jurisdictions. Furthermore, the new edition reports the significant changes in US and Japanese patent law and jurisprudence. For example, in the US a post-grant review system has been introduced, which is similar to the EPO's opposition proceedings. Japan has reintroduced an opposition system. As a consequence of the Myriad cases, compounds of nature can no longer be patented in the US, unless the claims relate to structural or functional variants thereof. A similar hurdle has been established in the US with respect to inventions related to diagnostics. The book is not only useful for advanced practioners, but also for beginners as an introduction and orientation to the field of biotechnology patents in their international context.
8
From Clones to Claims (2016)
~EN HC NWISBN: 9783452279996 bzw. 3452279995, vermutlich in Englisch, Heymann, Köln, Deutschland, gebundenes Buch, neu.
Lieferung aus: Deutschland, Next Day, Versandkostenfrei.
Erscheinungsdatum: 07.01.2016, Medium: Buch, Einband: Gebunden, Titel: From Clones to Claims, Titelzusatz: An Encyclopedia of the European Patent Office's Case Law on the Patentability of Biotechnology Inventions with a Comparison to the United States and Japanese Practice, Auflage: 6. Auflage von 2016 // 6. Auflage, Autor: Haley, James F. // Hosoda, Yoshinori // Jaenichen, Hans-Rainer // McDonell, Leslie A. // Meier, Jürgen, Verlag: Heymanns Verlag GmbH // Heymanns, Carl, Sprache: Englisch, Schlagworte: Biotechnologie // Biotechnik // Technologie // Europa // Europarecht // Internationales Recht // Handelsrecht // International // Recht // Patentrecht // Patentgesetz // PatG // Unternehmensrecht // Wettbewerbsrecht // Wettbewerbssache // Gesellschafts- // Handels // und Wettbewerbsrecht // allgemein, Rubrik: Internationales und ausländ. Recht, Seiten: 1578, Reihe: Heymanns Intellectual Property, Gewicht: 2183 gr, Verkäufer: averdo.
Erscheinungsdatum: 07.01.2016, Medium: Buch, Einband: Gebunden, Titel: From Clones to Claims, Titelzusatz: An Encyclopedia of the European Patent Office's Case Law on the Patentability of Biotechnology Inventions with a Comparison to the United States and Japanese Practice, Auflage: 6. Auflage von 2016 // 6. Auflage, Autor: Haley, James F. // Hosoda, Yoshinori // Jaenichen, Hans-Rainer // McDonell, Leslie A. // Meier, Jürgen, Verlag: Heymanns Verlag GmbH // Heymanns, Carl, Sprache: Englisch, Schlagworte: Biotechnologie // Biotechnik // Technologie // Europa // Europarecht // Internationales Recht // Handelsrecht // International // Recht // Patentrecht // Patentgesetz // PatG // Unternehmensrecht // Wettbewerbsrecht // Wettbewerbssache // Gesellschafts- // Handels // und Wettbewerbsrecht // allgemein, Rubrik: Internationales und ausländ. Recht, Seiten: 1578, Reihe: Heymanns Intellectual Property, Gewicht: 2183 gr, Verkäufer: averdo.
9
From Clones to Claims: The European Patent Office's Case Law on the Patentability of Biotechnology. Inventions in Comparison to the United States and Japanese Proctice (2006)
EN HC USISBN: 9783452247384 bzw. 3452247384, in Englisch, 881 Seiten, 4. Ausgabe, Heymanns, Carl, gebundenes Buch, gebraucht.
Lieferung aus: Deutschland, Auf Lager. Tatsächliche Versandkosten können abweichen.
Von Händler/Antiquariat, leydorf.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Von Händler/Antiquariat, leydorf.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
10
Symbolbild
From Clones to Claims: The European Patent Offices's Case Law on the Patentability of Biotechnology Investions in Comparison to the United States Japanese Practice (2006)
DE NWISBN: 9783452247384 bzw. 3452247384, in Deutsch, 4. Ausgabe, Heymanns, neu.
Von Händler/Antiquariat, primatexxt Buchversand [52930088], München, Germany.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…